Key result
Soluble S100A4 is ~5-fold higher in cardiac neonatal lupus cord blood and tracks disease severity.
Why the study?
Increased appreciation of fibroblast heterogeneity prompted re-examination of models of anti-SSA/Ro-associated cardiac neonatal lupus to evaluate distinct fibroblast subtypes.
Cross-Sectional (n=96)
Yes
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for S100A4 as biomarker in cardiac neonatal lupus; prospective validation required before any clinical use.
Background Fibrosis and dystrophic calcification disrupting conduction tissue architecture are histopathological lesions characterizing cardiac manifestations of neonatal lupus (cardiac-NL) associated with maternal anti-SSA/Ro antibodies. Objectives Increased appreciation of heterogeneity in fibroblasts encourages re-examination of existing models with the consideration of multiple fibroblast subtypes (and their unique functional differences) in mind. This study addressed fibroblast heterogeneity by examining expression of α-Smooth Muscle Actin (myofibroblasts) and of S100 Calcium-Binding Protein A4 (S100A4). Methods Using a previously established model of rheumatic scarring/fibrosis in vitro , supported by the evaluation of cord blood from cardiac-NL neonates and their healthy (anti-SSA/Ro-exposed) counterparts, and autopsy tissue from fetuses dying with cardiac-NL, the current study was initiated to more clearly define and distinguish the S100A4-positive fibroblast in the fetal cardiac environment. Results S100A4 immunostaining was observed in 4 cardiac-NL hearts with positional identity in the conduction system at regions of dystrophic calcification but not fibrotic zones, the latter containing only myofibroblasts. In vitro , fibroblasts cultured with supernatants of macrophages transfected with hY3 (noncoding ssRNA) differentiated into myofibroblasts or S100A4 + fibroblasts. Myofibroblasts expressed collagen while S100A4 + fibroblasts expressed pro-angiogenic cytokines and proteases that degrade collagen. Cord blood levels of S100A4 in anti-SSA/Ro-exposed neonates tracked disease severity and, in discordant twins, distinguished affected from unaffected. Conclusions These findings position the S100A4 + fibroblast alongside the canonical myofibroblast in the pathogenesis of cardiac-NL. Neonatal S100A4 levels support a novel biomarker of poor prognosis.
No takes yet. Share an insight, caveat, or question.
Firl et al. (2023) conducted a cross-sectional in Cardiac manifestations of neonatal lupus (cardiac-NL) (n=96). Cardiac-NL vs. Healthy anti-SSA/Ro-exposed neonates was evaluated on Soluble S100A4 levels in umbilical cord blood (p=<0.0001). Soluble S100A4 was elevated in the cord blood of neonates with cardiac neonatal lupus compared to healthy exposed neonates and tracked with disease severity.
Synapse has enriched 10 related papers. Consider them for comparative context: